Hospital Acquired Infections Diagnostics Market To Reach $7.15 Billion By 2030

Hospital Acquired Infections Diagnostics Market Growth & Trends

The global hospital acquired infections diagnostics market is expected to reach USD 7.15 billion by 2030, according to a new report by Grand View Research, Inc. The global hospital acquired infections diagnostics market is projected to grow at a healthy CAGR of 7.2% during the period of 2023 to 2030. Factors attributing to the growth of the market are increase in the number of drug-resistant pathogens such as MRSA and C. difficile, advancing age of geriatric population, and development of technologically advanced products that offer accurate and reliable results with low turnaround time. 

Another factor contributing to industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely to hinder industry growth. 

The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented into Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated to account for the largest share, whereas the pneumonia HAI diagnostics is projected to grow at the highest CAGR during the period of 2015 to 2022.The HAI diagnostics industry is further segmented into molecular tests and other in-vitro tests. Though the molecular diagnostics segment is estimated to constitute a low share, it is anticipated to witness a lucrative growth in the next few years.

 Request a free sample copy or view report summary: Hospital Acquired Infections Diagnostics Market Report

Hospital Acquired Infections Diagnostics Market Report Highlights

• The consumables segment held the largest revenue share of 63.5% in the hospital acquired infections diagnostics market in 2022 and is expected to expand at the fastest CAGR of 7.7% over the forecast period, owing to the rising incidence of HAIs.

• The blood tests segment accounted for the largest revenue share of 65.8% in 2022 and is expected to advance at the fastest CAGR of 7.08% during the forecast period.

• Europe dominated the market and accounted for the largest revenue share of 34.3% in 2022, owing to the high disease burden, the availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and the presence of major players. 

Hospital Acquired Infections Diagnostics Market Segmentation

Grand View Research has segmented the global hospital acquired infections diagnostics market report on the basis of test type, infection type, product, type, and region:

Hospital Acquired Infections Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Molecular

• Conventional

Hospital Acquired Infections Diagnostics Infection Type Outlook (Revenue, USD Million, 2018 - 2030)

• UTI

• Pneumonia

• Surgical Site Infection 

• Blood Stream Infections

• Others

Hospital Acquired Infections Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Consumables

• Instruments

Hospital Acquired Infections Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Tests

• Urinalysis

Hospital Acquired Infections Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030) 

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Hospital Acquired Infections (HAI) Diagnostics Market

• BIOMÉRIEUX

• Abbott

• F. Hoffmann-La Roche Ltd.

• Siemens Healthcare Private Limited

• BD (Becton, Dickinson and Company)

• Bioscience, Inc.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Meridian Bioscience, Inc.

• Hologic, Inc.